reuters.com · 16 jul

Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst

Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker ​Catalyst Pharmaceuticals in a $4.1 billion deal involving ‌Italian state lender CDP.

globenewswire.com · 16 jul

Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.

marketbeat.com · 10 jul

Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger

Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.

zacks.com · 2 jul

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data

Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.

globenewswire.com · 30 jun

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses

gurufocus.com · 25 jun

Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?

Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026

gurufocus.com · 24 jun

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propo

businesswire.com · 24 jun

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led t.